New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced that its RaDaR® ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) to include immunotherapy monitoring for patients with late-stage solid tumors.

Medicare coverage for RaDaR ST now includes monitoring of response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors.1 This is the third Medicare-covered indication for RaDaR ST, which also includes HPV-negative head and neck squamous cell carcinoma and a subset of hormone receptor-positive (HR+), HER2-negative breast cancer. NeoGenomics also has two additional RaDaR ST submissions pending with MolDX.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.